Incyte: This Profitable Biotech Trades Like A Melting Iceberg (NASDAQ:INCY)

Core Insights - Incyte Corporation (INCY) is a profitable late-stage biotech firm with a market capitalization of approximately $20 billion, indicating strong financial health and growth potential [1] Company Overview - INCY's revenue and earnings base is diversifying, suggesting a robust business model that may lead to sustained growth [1]